X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dabur Pharma: Oncology drives growth - Views on News from Equitymaster
MidCapSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dabur Pharma: Oncology drives growth
Jan 24, 2007

Dabur Pharma has announced robust results for the third quarter and nine-months ended December 2006. The company’s strong presence in the oncology segment in both India and the semi-regulated or less regulated markets has led to the strong growth in topline. Operating margins have also expanded, chiefly owing to a reduction in other expenditure, R&D and staff costs (as percentage of sales). All these factors put together have led to the bottomline growth keeping pace with the growth in topline during the quarter.

Financial performance: A snapshot
(Rs m) 3QFY06 3QFY07 Change 9mFY06 9mFY07 Change
Net sales 710 836 17.7% 2,175 2,625 20.7%
Expenditure 616 711 15.4% 1,937 2,306 19.1%
Operating profit (EBIDTA) 95 126 32.9% 237 318 34.3%
Operating profit margin (%) 13.3% 15.0%   10.9% 12.1%  
Other income 11 14 27.9% 29 33 14.2%
Interest 7 21 221.3% 20 50 145.1%
Depreciation 10 15 40.2% 30 38 26.8%
Profit before tax 89 104 17.2% 216 264 22.2%
Tax 13 15 11.9% 33 39 18.8%
Profit after tax/ (loss) 76 89 18.0% 183 225 22.8%
Net profit margin (%) 10.7% 10.7%   8.4% 8.6%  
No. of shares (m) 156.1 156.2   156.1 156.2  
Diluted earnings per share (Rs)*         1.5  
P/E ratio (x)*         53.3  

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - DR. DATSONS LABS COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS